Indivior (NASDAQ:INDV) Sees Large Volume Increase – Time to Buy?

Indivior PLC (NASDAQ:INDV) shares saw strong trading volume on Friday . 8,737,425 shares were traded during mid-day trading, an increase of 312% from the previous session’s volume of 2,121,490 shares.The stock last traded at $31.0260 and had previously closed at $30.86.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on INDV shares. Morgan Stanley reaffirmed an “overweight” rating and set a $36.00 price objective on shares of Indivior in a research note on Wednesday, December 3rd. Weiss Ratings raised Indivior from a “hold (c)” rating to a “buy (b-)” rating in a research note on Monday, March 2nd. Northland Securities set a $50.00 target price on Indivior in a report on Tuesday, January 20th. Zacks Research lowered Indivior from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 13th. Finally, HC Wainwright upped their price target on Indivior from $35.00 to $48.00 and gave the company a “buy” rating in a research note on Monday, January 12th. Six investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $39.33.

Indivior Trading Up 0.8%

The firm’s fifty day moving average price is $33.73 and its 200-day moving average price is $30.62. The company has a market cap of $3.89 billion, a price-to-earnings ratio of 18.97 and a beta of 0.83.

Indivior (NASDAQ:INDV) last issued its quarterly earnings data on Thursday, February 26th. The company reported $0.82 EPS for the quarter, topping the consensus estimate of $0.65 by $0.17. The business had revenue of $358.00 million for the quarter, compared to the consensus estimate of $305.62 million. Indivior had a negative return on equity of 148.76% and a net margin of 16.85%. As a group, research analysts anticipate that Indivior PLC will post 1.22 EPS for the current year.

Insider Activity at Indivior

In other Indivior news, Director Daniel A. Ninivaggi acquired 775 shares of the firm’s stock in a transaction that occurred on Monday, January 5th. The stock was acquired at an average cost of $35.39 per share, for a total transaction of $27,427.25. Following the transaction, the director owned 16,923 shares of the company’s stock, valued at $598,904.97. This trade represents a 4.80% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Keith Humphreys bought 775 shares of the stock in a transaction that occurred on Monday, January 5th. The shares were acquired at an average cost of $35.39 per share, with a total value of $27,427.25. Following the completion of the purchase, the director owned 5,802 shares in the company, valued at $205,332.78. This represents a 15.42% increase in their position. The SEC filing for this purchase provides additional information. Insiders have acquired a total of 5,842 shares of company stock valued at $203,342 over the last 90 days.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the stock. Oaktree Capital Management LP increased its position in shares of Indivior by 2,241.6% during the third quarter. Oaktree Capital Management LP now owns 257,785,398 shares of the company’s stock worth $6,215,206,000 after acquiring an additional 246,776,273 shares in the last quarter. Two Seas Capital LP lifted its position in Indivior by 0.4% in the 2nd quarter. Two Seas Capital LP now owns 11,407,795 shares of the company’s stock valued at $168,151,000 after acquiring an additional 41,018 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in Indivior by 18.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 8,368,996 shares of the company’s stock worth $79,757,000 after purchasing an additional 1,299,425 shares during the period. Fuller & Thaler Asset Management Inc. boosted its stake in Indivior by 101.0% in the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 6,371,534 shares of the company’s stock worth $228,611,000 after purchasing an additional 3,201,639 shares during the period. Finally, Vanguard Group Inc. increased its holdings in Indivior by 57.9% during the 4th quarter. Vanguard Group Inc. now owns 5,473,891 shares of the company’s stock worth $196,403,000 after purchasing an additional 2,008,078 shares in the last quarter. Institutional investors own 60.33% of the company’s stock.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.